Jingying Zhou

Title: Innovations and Contributions of Inventor Jingying Zhou

Introduction

Jingying Zhou is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 3 patents, his work has the potential to impact the treatment of autoimmune disorders.

Latest Patents

One of Jingying Zhou's latest patents is focused on antibodies against a novel isoform of the human PD1 protein, specifically the isoform known as Δ42PD1. This isoform contains a 42-nucleotide in-frame deletion in exon 2. The invention details methods for using these antibodies in the treatment of autoimmune disorders. In certain embodiments, the antibodies against Δ42PD1 are monoclonal, showcasing the innovative approach taken by Zhou in addressing complex medical challenges.

Career Highlights

Throughout his career, Jingying Zhou has worked with reputable organizations such as Versitech, Inc. and The University of Hong Kong. His experience in these institutions has allowed him to collaborate with other experts in the field and further his research endeavors.

Collaborations

Jingying Zhou has collaborated with notable colleagues, including Zhiwei Chen and Lin Cheng. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Jingying Zhou's innovative work in the field of biotechnology, particularly in the development of antibodies for autoimmune disorders, highlights his significant contributions as an inventor. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.